A niche biotech player in the cannabis sector seeking to monetize R&D through proprietary solutions despite significant accumulated deficits and negative cash flow from operations.
An investor might consider CBIH for its high-risk, high-reward profile in the biotech sector where a successful product launch could yield substantial upside potential. The company's focus on proprietary bioscience solutions positions it to capture value as the cannabis market matures and regulatory clarity improves. Early-stage investors may view the current cash burn as a temporary hurdle before the next major revenue milestone or strategic partnership.
The stock is highly speculative given the massive accumulated deficit of nearly $6 million and total liabilities of $1.2 million against negligible equity. Negative operating cash flow of over $300k indicates the business model has not yet achieved commercial viability or self-sufficiency. Investors face elevated risk of dilution through frequent financing rounds to cover operational losses in a market with limited historical profitability.
Cannabis Bioscience International Holdings, Inc. (CBIH) is a specialized entity operating within the emerging cannabis biotechnology sector, focusing on research and development initiatives to serve markets in North America and beyond. The company leverages its platform to develop proprietary products aimed at enhancing agricultural efficiency and product quality in the regulated cannabis industry. Despite recent operational losses, the firm maintains a lean asset structure while navigating the complex regulatory landscape of the cannabis space.
CBIH reported a net loss of $548,820 for the period, driven by operating expenses totaling $684,281 which far exceeded gross profits of $262,916. Cash flow from operations turned negative at -$329,627, necessitating substantial cash inflows from financing activities of $341,824 to avoid insolvency. While current assets sit at $29,085 and the company retained some liquidity with ending cash of $12,952, the burn rate remains unsustainable without a significant increase in revenue or strategic capital injection.
The global cannabis industry is expanding rapidly as legalization spreads, creating demand for innovative cultivation technologies and product formulations. Biotech firms are increasingly seeking to integrate science-driven solutions to improve yield, potency, and safety profiles across the supply chain. However, the sector remains fragmented and capital-intensive, with many players struggling to transition from research phases to consistent commercial profitability.
| Metric | 2024 | 2025 |
|---|---|---|
| Revenue | $248.8K | $303.0K |
| Cost of Revenue | $45.6K | $40.1K |
| Gross Profit | $203.2K | $262.9K |
| Operating Expenses | $689.4K | $684.3K |
| Operating Income | $-486.1K | $-421.4K |
| G&A | $123.8K | $101.9K |
| Stock-Based Comp | $0 | — |
| Other OpEx | $565.6K | $582.4K |
| Non-Operating Income | $0 | $0 |
| Pre-Tax Income | $-486.1K | $-421.4K |
| Income Tax | $0 | $127.5K |
| Continuing Ops | $-486.1K | $-548.8K |
| Discontinued Ops | $0 | $0 |
| Net Income | $-651.3K | $-548.8K |
| Minority Interest | $0 | $0 |
| Net to Common | $-651.3K | $-548.8K |
| Metric | 2024 | 2025 |
|---|---|---|
| Current Assets | $21.5K | $29.1K |
| Accounts Receivable | $20.1K | $6.4K |
| Other Current Assets | $1.4K | $22.7K |
| Long-Term Assets | $35.7K | $2.8K |
| Operating Leases | $35.7K | $2.8K |
| Other LT Assets | $0 | $0 |
| Total Assets | $57.2K | $31.9K |
| Current Liabilities | $881.9K | $946.0K |
| Current Debt | $7.1K | $14.6K |
| Current Leases | $21.9K | $4.9K |
| Other Current Liab | $853.0K | $926.5K |
| Long-Term Liabilities | $254.3K | $249.5K |
| Long-Term Debt | $249.4K | $249.5K |
| LT Operating Leases | $4.9K | $0 |
| Other LT Liab | $0 | $0 |
| Total Liabilities | $1.1M | $1.2M |
| Shareholders' Equity | $-1.1M | $-1.2M |
| Paid-In Capital | $4.3M | $4.7M |
| Retained Earnings | $-5.3M | $-5.9M |
| Total L&E | $57.2K | $31.9K |
| Metric | 2024 | 2025 |
|---|---|---|
| Net Income (CFO) | $-651.3K | $-548.8K |
| Non-Cash Adjustments | $83.3K | $289.0K |
| Working Capital Changes | $88.7K | $-69.8K |
| Cash from Operations | $-479.4K | $-329.6K |
| Cash from Investing | $0 | $0 |
| Cash from Financing | $471.2K | $341.8K |
| FX Effect | $0 | $0 |
| Net Change in Cash | $-8.2K | $12.2K |
| Beginning Cash | $8.9K | $755 |
| Ending Cash | $755 | $13.0K |
The company's revenue primarily stems from product sales and licensing agreements related to its bioscience portfolio, with gross profit indicating successful cost management on core offerings. Revenue streams are currently concentrated in early-stage commercialization efforts rather than diversified mature markets. Operations include R&D expenditures and general administrative costs typical of a pre-profitability biotech firm.
The company faces severe liquidity constraints evidenced by negative operating cash flow and a significant retained earnings deficit exceeding $5.9 million. Heavy reliance on external financing is required to sustain operations given the inability to generate positive cash flow from core activities. The cannabis industry remains subject to volatile regulatory environments and potential market consolidation that could further erode margins. Limited revenue base of roughly $0.3 million exposes the firm to high volatility in a nascent and competitive market.
The company possesses unique proprietary intellectual property focused on cannabis cultivation optimization and product enhancement, creating a technological moat against generic competitors. Its specialized bioscience platform allows for targeted development cycles that could accelerate time-to-market for new regulated cannabis products. The organization maintains a lean operational footprint with minimal long-term assets, preserving capital for strategic pivots or acquisition opportunities.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.